Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Supreme Court Abstains From Drugs: Will Not Review J&J Vs. Abbott; Takes No Action On Gene Patents

This article was originally published in The Pink Sheet Daily

Executive Summary

The high court denied J&J’s request for review of a Federal Circuit decision that overturned a $1.67 billion jury verdict against Abbott’s Humira; it made no decision on ACLU’s petition for review of Myriad Genetics’ BRCA gene patents.

You may also be interested in...

Supreme Court Overturns Personalized Medicine Patents, Creating Confusion In Diagnostics Realm

High court rules the processes covered by two patents to determine proper drug dosages based on metabolite concentrations do not transform unpatentable natural laws into patent-eligible applications.

Supreme Court Overturns Drug Calibration Patents, Creating Confusion In Biotech Realm

The court’s finding that Prometheus’ drug calibration test is unpatentable has left the biotech community reeling with uncertainty as to whether method of treatment claims, particularly those involving biomarkers, will be patent eligible.

Drug Calibration Patents Under Scrutiny As Supreme Court Weighs How To Build On Law Of Nature

During oral arguments in Mayo v. Prometheus, justices question what standard to apply in assessing whether the correlation of a drug’s metabolites to proper dosage is patentable; ACLU petitions court to review Myriad gene patent case.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts